Cell-therapy for Parkinson’s disease: a systematic review and meta-analysis DOI Creative Commons
Fang Wang, Zhengwu Sun,

Daoyong Peng

et al.

Journal of Translational Medicine, Journal Year: 2023, Volume and Issue: 21(1)

Published: Sept. 7, 2023

Cell-based strategies focusing on replacement or protection of dopaminergic neurons have been considered as a potential approach to treat Parkinson's disease (PD) for decades. However, despite promising preclinical results, clinical trials cell-therapy PD reported mixed outcomes and thorough synthesis these findings is lacking. We performed systematic review meta-analysis evaluate patients.We systematically identified all investigating cell- tissue-based therapies published before July 2023. Out those, studies reporting transplantation homogenous cells (containing one cell type) were included in meta-analysis. The mean difference standardized quantitative neurological scale scores after was analyzed treatment effects.The literature search revealed 106 articles. Eleven data from 11 independent (210 patients) eligible Disease severity motor function evaluation indicated beneficial effects the 'off' state at 3-, 6-, 12-, 24-month follow-ups, even 36 months. Most patients levodopa responders (61.6-100% different follow-ups). Cell-therapy also effective improving daily living activities patients. Cells diverse sources used multiple modes applied. Autografts did not improve functional outcomes, while allografts exhibited effects. Encouragingly, both into basal ganglia areas outside reduce severity. Some adverse events potentially related surgical procedure. One confirmed four possible cases graft-induced dyskinesia two this meta-analysis.This provides preliminary evidence PD, responders. Allogeneic superior autologous cells, sites are limited ganglia. PROSPERO registration number: CRD42022369760.

Language: Английский

Neurogenesis in aging and age-related neurodegenerative diseases DOI Creative Commons

Luka Čulig,

Xixia Chu,

Vilhelm A. Bohr

et al.

Ageing Research Reviews, Journal Year: 2022, Volume and Issue: 78, P. 101636 - 101636

Published: April 29, 2022

Language: Английский

Citations

117
New era of artificial intelligence and machine learning-based detection, diagnosis, and therapeutics in Parkinson’s disease DOI

Rohan Gupta,

Smita Kumari,

Anusha Senapati

et al.

Ageing Research Reviews, Journal Year: 2023, Volume and Issue: 90, P. 102013 - 102013

Published: July 8, 2023

Language: Английский

Citations

55
Autophagy‐associated non‐coding RNAs: Unraveling their impact on Parkinson's disease pathogenesis DOI Creative Commons
Md Sadique Hussain, Ehssan Moglad, Muhammad Afzal

et al.

CNS Neuroscience & Therapeutics, Journal Year: 2024, Volume and Issue: 30(5)

Published: May 1, 2024

Parkinson's disease (PD) is a degenerative neurological condition marked by the gradual loss of dopaminergic neurons in substantia nigra pars compacta. The precise etiology PD remains unclear, but emerging evidence suggests significant role for disrupted autophagy-a crucial cellular process maintaining protein and organelle integrity.

Language: Английский

Citations

19
A Comprehensive Approach to Parkinson’s Disease: Addressing Its Molecular, Clinical, and Therapeutic Aspects DOI Open Access
Mauricio Muleiro Álvarez, Gabriela Cano-Herrera,

María Fernanda Osorio Martínez

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(13), P. 7183 - 7183

Published: June 29, 2024

Parkinson's disease (PD) is a gradually worsening neurodegenerative disorder affecting the nervous system, marked by slow progression and varied symptoms. It second most common disease, over six million people in world. Its multifactorial etiology includes environmental, genomic, epigenetic factors. Clinical symptoms consist of non-motor motor symptoms, with being classic presentation. Therapeutic approaches encompass pharmacological, non-pharmacological, surgical interventions. Traditional pharmacological treatment consists administering drugs (MAOIs, DA, levodopa), while emerging evidence explores potential antidiabetic agents for neuroprotection gene therapy attenuating parkinsonian Non-pharmacological treatments, such as exercise, calcium-rich diet, adequate vitamin D supplementation, aim to prevent complications. For those patients who have medically induced side effects and/or refractory surgery therapeutic option. Deep brain stimulation primary option, associated symptom improvement. Levodopa/carbidopa intestinal gel infusion through percutaneous endoscopic gastrojejunostomy portable pump succeeded reducing "off" time, where occur, increasing "on" time. This article aims address general aspects PD provide comparative comprehensive review conventional latest advancements treatments PD. Nevertheless, further studies are required optimize suitable alternatives.

Language: Английский

Citations

16
Recent advances in nanotechnology for Parkinson’s disease: diagnosis, treatment, and future perspectives DOI Creative Commons
Virendra Kumar Yadav, Seshathiri Dhanasekaran, Nisha Choudhary

et al.

Frontiers in Medicine, Journal Year: 2025, Volume and Issue: 12

Published: Jan. 22, 2025

Parkinson’s disease is a progressive neurodegenerative that destroys substantia nigra dopaminergic neurons, causing tremors, bradykinesia, rigidity, and postural instability. Current treatment approaches primarily focus on symptom management, employing pharmacological, non-pharmacological, surgical methods. However, these treatments often result in fluctuating symptoms, side effects, progression. Here, the authors have reviewed emerging field of nanomedicine as promising path for treatment, emphasizing its potential to overcome limitations traditional therapies. Nanomedicine utilizes nanoparticles targeted drug delivery, leveraging their small size high surface area volume ratio cross blood-brain barrier deliver therapeutic agents directly affected brain regions. Various nanoparticles, including lipid-based, polymeric, metallic, carbon-based, shown treatment. Additionally, nanocarrier systems like liposomes, nanogels, dendrimers, solid lipid offer controlled sustained release agents, enhancing bioavailability reducing effects. This review provides insights into pathophysiology disease, highlighting mechanisms neurodegeneration, role alpha-synuclein, disruption pathways. It further discusses application gene therapy conjunction with interventions.

Language: Английский

Citations

2
SIRT1 pathway in Parkinson’s disease: a faraway snapshot but so close DOI Creative Commons
Gaber El‐Saber Batiha, Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb

et al.

Inflammopharmacology, Journal Year: 2022, Volume and Issue: 31(1), P. 37 - 56

Published: Dec. 29, 2022

Abstract Silent information regulator (SIRT) has distinctive enzymatic activities and physiological functions to control cell-cycle progression, gene expression, DNA stability by targeting histone non-histone proteins. SIRT1 enhances synaptic formation activity, therefore, can reduce the progression of various degenerative brain diseases including Parkinson’s disease (PD). activity is decreased aging with a subsequent increased risk for development diseases. Inhibition promotes inflammatory reactions since inhibits transcription nuclear factor kappa B (NF-κB) which also activation via microRNA miR-34a NAD synthesis. highly expressed in microglia as well neurons, antioxidant anti-inflammatory effects. Therefore, this review aimed find possible role PD neuropathology. neuroprotective effects; downregulation during p53 expression may increase vulnerability neuronal cell deaths. neuropathology linked sequence changes release pro-inflammatory cytokines due signaling pathways. In addition, oxidative stress, disorders, mitochondrial dysfunction, apoptosis contribute mutually Thus, activators play crucial mitigation through amelioration apoptosis,

Language: Английский

Citations

68
Sensitive immunosensing of α-synuclein protein in human plasma samples using gold nanoparticles conjugated with graphene: an innovative immuno-platform towards early stage identification of Parkinson's disease using point of care (POC) analysis DOI Creative Commons

Esmaeil Darvish Aminabad,

Ahmad Mobed, Mohammad Hasanzadeh

et al.

RSC Advances, Journal Year: 2022, Volume and Issue: 12(7), P. 4346 - 4357

Published: Jan. 1, 2022

Parkinson's disease (PD) or simply is a long-term degenerative disorder of the central nervous system, which mainly affects motor system. Consequently, detection and quantification related biomarkers play vital roles in early-stage diagnosis PD. In present study, an innovative electrochemical immunosensor based on gold nanoparticle-modified graphene towards bioconjugation with biotinylated antibody (bioreceptor) was developed for ultra-sensitive specific monitoring alpha-synuclein (α-synuclein) protein. The synergistic effects between nanoparticles (AuNPs) drastically enhanced activity resulting materials. conductivity substrate together increase its surface area improved sensitivity lowered limit capture layer. For first time, α-synuclein protein measured human plasma samples using bioconjugated AuNP-Gr acceptable linear range 4 to 128 ng mL

Language: Английский

Citations

45
Current Treatments and New, Tentative Therapies for Parkinson’s Disease DOI Creative Commons
Teresa Pardo-Moreno, Victoria García‐Morales, Nora Suleiman‐Martos

et al.

Pharmaceutics, Journal Year: 2023, Volume and Issue: 15(3), P. 770 - 770

Published: Feb. 25, 2023

Parkinson’s disease (PD) is a neurodegenerative pathology, the origin of which associated with death neuronal cells involved in production dopamine. The prevalence PD has increased exponentially. aim this review was to describe novel treatments for that are currently under investigation and study possible therapeutic targets. pathophysiology based on formation alpha-synuclein folds generate Lewy bodies, cytotoxic reduce dopamine levels. Most pharmacological target symptoms. These include aimed at reducing accumulation (epigallocatechin), its clearance via immunotherapy, inhibiting LRRK2, upregulating cerebrosidase (ambroxol). continues be pathology unknown generates significant social cost patients who suffer from it. Although there still no definitive cure present, numerous available symptomatology addition other alternatives investigation. However, approach should combination non-pharmacological strategies maximise outcomes improve symptomatological control these patients. It therefore necessary delve deeper into order quality life

Language: Английский

Citations

39
Parkinson’s Disease Risk and Hyperhomocysteinemia: The Possible Link DOI Creative Commons
Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, Yaser Hosny Ali Elewa

et al.

Cellular and Molecular Neurobiology, Journal Year: 2023, Volume and Issue: 43(6), P. 2743 - 2759

Published: April 19, 2023

Abstract Parkinson’s disease (PD) is one of the most common degenerative brain disorders caused by loss dopaminergic neurons in substantia nigra (SN). Lewy bodies and -synuclein accumulation SN are hallmarks neuropathology PD. Due to lifestyle changes prolonged L-dopa administration, patients with PD frequently have vitamin deficiencies, especially folate, B6, B12. These augment circulating levels Homocysteine development hyperhomocysteinemia, which may contribute pathogenesis Therefore, this review aimed ascertain if hyperhomocysteinemia play a part oxidative inflammatory signaling pathways that development. Hyperhomocysteinemia implicated neurodegenerative disorders, including triggers progression different mechanisms, stress, mitochondrial dysfunction, apoptosis, endothelial dysfunction. Particularly, linked high systemic disorders. induces immune activation stress. In turn, activated response promotes hyperhomocysteinemia. hyperhomocysteinemia-induced immunoinflammatory abnormal aggravate PD, leading more severity. Also, like nuclear factor kappa B (NF-κB) nod-like receptor pyrin 3 (NLRP3) inflammasome other intricate conclusion, involved either directly via induction degeneration or indirectly pathways.

Language: Английский

Citations

38
The Promise of Niacin in Neurology DOI Creative Commons
Emily Wuerch, Gloria Roldan Urgoiti, V. Wee Yong

et al.

Neurotherapeutics, Journal Year: 2023, Volume and Issue: 20(4), P. 1037 - 1054

Published: April 21, 2023

Language: Английский

Citations

32